Browsing by Author "Mutlu E."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Reliability and validity study of the Turkish version of the clinical opiate clinical scale; [Klinik opiyat yoksunluk ölçeği (clinical opiate withdrawal scale-cows) Türkçe sürümünün güvenilirliği ve geçerliliği]
    (Turkish Neuropsychiatric Society, 2015) Altintoprak A.E.; Evren E.C.; Aydemir Ö.; Yapici-Eslek A.; Can Y.; Mutlu E.; Tokuçoğlu L.; Deveci A.; Coşkunol H.
    Introduction: The aim of the present study was to perform reliability and validity analyses of the Turkish version of the Clinical Opiate Withdrawal Scale which is used to determine the severity of opiate withdrawal. Methods: Initially, the Clinical Opiate Withdrawal Scale (COWS) was translated into Turkish and subsequently back-translated into English. The originality of the back-translated version was approved by the author who developed the scale. After the translation was completed, the scale was used to assess the withdrawal symptoms of 100 patients with opiate withdrawal and 41 patients with alcohol withdrawal. Cronbach’s alpha was used in the reliability assessment; explanatory and confirmatory factor analyses were used in structural validity assessment; and in scale validity, ROC analysis was used among diagnosis groups. Results: The Cronbach’s alpha internal consistency coefficient was calculated as 0.74 in reliability analyses. The correlation coefficient was found to be 0.975 (p<0.001) for inter-rater reliability. Factor analysis was conducted for the structural validity of the scale and findings that support the unidimensional structure of the scale were observed. In the confirmatory factor analysis, CFI, GFI and RMSEA values were found to be 0.905, 0.905 and 0.079, respectively. It was detected that COWS was successful in distinguishing between opiate and alcohol withdrawal symptoms and the area under the ROC curve was 0.878. Conclusion: This study showed that the Turkish version of COWS can be used reliably and validly for assessing opiate withdrawal. © 2015 by Turkish Association of Neuropsychiatry.
  • No Thumbnail Available
    Item
    Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study
    (Blackwell Publishing Ltd, 2018) Aksoy B.; Hapa A.; Mutlu E.
    Background: The literature includes only a few reports of oral isotretinoin for the treatment of folliculitis decalvans (FD). This study aimed to determine the most effective dose and duration of oral isotretinoin monotherapy for achieving remission in FD patients. Methods: This retrospective case series study included FD patients that were treated with oral isotretinoin. Patient demographics, clinical characteristics, and treatment details were obtained from the patients’ medical records. Patients were contacted via telephone after treatment was completed and asked about any relapses, time period of relapses, and the long-term effects of the treatment. Results: The study included 39 male patients with a mean age of 37.9 ± 15.5 years. All of the patients received oral isotretinoin 0.1–1.02 mg/kg/day (10–90 mg/day) for a median duration of 2.5 months (range: 1–8 months). In all, 82.0% of patients healed after the treatment. Patients that received oral isotretinoin ≥0.4 mg/kg/day for ≥3 months responded better, and 66% of them never relapsed. Conclusion: Contrary to general belief, oral isotretinoin monotherapy resulted in complete response in the majority of patients in this study. Based on this finding, we think oral isotretinoin ≥0.4 mg/kg/day should be given for ≥3 months to minimize the likelihood of relapse. In addition, we think oral isotretinoin monotherapy should be considered a promising treatment alternative for FD that warrants further research. © 2017 The International Society of Dermatology.
  • No Thumbnail Available
    Item
    Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
    (Churchill Livingstone, 2022) Yıldırım H.Ç.; Mutlu E.; Chalabiyev E.; Özen M.; Keskinkılıç M.; Ön S.; Çelebi A.; Dursun B.; Acar Ö.; Kahraman S.; Aykan M.B.; Kaman Ö.; Doğan A.; Erdoğan A.P.; Melisa Celayir Ö.; Günenç D.; Güven D.C.; Vedat Bayoğlu İ.; Yavuzşen T.; Hacıbekiroğlu İ.; İnanç M.; Kılıçkap S.; Yalçın Ş.; Aksoy S.
    Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4–6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4–6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04–25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4–6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4–6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4–6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer. © 2022
  • No Thumbnail Available
    Item
    The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
    (Springer, 2024) Yıldırım H.Ç.; Kutlu Y.; Mutlu E.; Aykan M.B.; Korkmaz M.; Yalçın S.; Şakalar T.; Celayir Ö.M.; Kayıkçıoğlu E.; Aslan F.; Hafızoğlu E.; Altıntaş Y.E.; Keskinkılıç M.; Chalabiyev E.; Çelebi A.; Dursun B.; Kapar C.; Özen M.; Acar Ö.; Dülgar Ö.; Kut E.; Biter S.; Kus F.; Almuradova E.; Erdoğan A.P.; Saray S.; Güven D.C.; Şimşek E.T.; Üskent N.; Kemal Y.; Çakar B.; Açıkgöz Ö.; Kılıçkap S.; Aksoy S.
    Introduction: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 −) breast cancer in women, limited data exist on their effectiveness in male patients. We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer. Methods: This study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects. Results: A total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 ± 13.69 years, with a median follow-up of 21.33 (95% CI 14.92–27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70–37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51–37.42) vs 28.33 months (95% CI 14.77–41.88), respectively, p = 0.211). No new adverse events were reported. Discussion: This study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 − metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population. © The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2024.